Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | CCR8 | P51685 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.31 |
| ▸ | ERN1 | O75460 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29836949 | 1.00 | CCR1 (0.32) | CCR1CCR5CCR8MEN1ALDH1A1 | |
| SCHEMBL31492595 | 0.81 | MEN1 (0.38) | CCR1CCR5CCR8MEN1ALDH1A1 | |
| SCHEMBL846251 | 0.81 | MEN1 (0.38) | CCR1CCR5CCR8MEN1ALDH1A1 | |
| SCHEMBL18297654 | 0.78 | ERN1 (0.35) | CCR1CCR5CCR8MEN1ALDH1A1 | |
| SCHEMBL25195292 | 0.77 | ALDH1A1 (0.48) | CCR1CCR5CCR8MEN1ALDH1A1 | |
| SCHEMBL30356708 | 0.77 | ALDH1A1 (0.48) | CCR1CCR5CCR8MEN1ALDH1A1 | |
| SCHEMBL26457513 | 0.77 | CCR1 (0.33) | CCR1CCR5CCR8MEN1ALDH1A1 | |
| SCHEMBL4322219 | 0.75 | ERN1 (0.38) | CCR1CCR5CCR8MEN1ALDH1A1 | |
| SCHEMBL31146149 | 0.75 | NR4A2 (0.32) | CCR1CCR5CCR8MEN1ALDH1A1 | |
| SCHEMBL5006077 | 0.75 | ERN1 (0.41) | CCR1CCR5CCR8MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 258 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637467-B2 | Inhibitor of BTK and mutants thereof | NEWAVE PHARMACEUTICAL INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-12441743-B2 | Spiro aromatic ring compound and use thereof | ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2025-10-14 | — | — | US | disclosed |
| US-20250214970-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2025-07-03 | — | — | US | disclosed |
| US-20250059189-A1 | PYRIDINE DERIVATIVES AND THEIR USE AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2025-02-20 | — | — | US | disclosed |
| EP-4055019-B1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS INC (US) | 2025-01-22 | — | — | EP | disclosed |
| US-12054486-B2 | Pyridine derivatives and their use as sodium channel activators | XENON PHARMACEUTICALS INC. (CA) | 2024-08-06 | — | — | US | disclosed |
| EP-4405347-A1 | PYRIDINE DERIVATIVES AND THEIR USE AS SODIUM CHANNEL ACTIVATORS | Xenon Pharmaceuticals Inc. (CA) | 2024-07-31 | — | — | EP | disclosed |
| CN-118271240-A | Protein site-specific labeling probe and labeling method based on reversible Michael addition triggering o-group participating reaction | 南开大学 | 2024-07-02 | — | — | CN | disclosed |
| CN-118284602-A | Pyridine derivatives as sodium channel activators and uses thereof | 泽农医药公司 | 2024-07-02 | — | — | CN | disclosed |
| US-20240116949-A1 | SPIRO AROMATIC RING COMPOUND AND USE THEREOF | ETERN BIOPHARMA SHANGHAI CO LTD (CN) | 2024-04-11 | — | — | US | disclosed |
| WO-2005070891-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2005-08-04 | — | — | WO | disclosed |
| CN-1552712-A | New camptothecin analogue compounds, a process for their preparation and pharmaceutical compositions containing them | ɪά��ʵ���� | 2004-12-08 | — | — | CN | disclosed |
| CN-1158282-C | Camptothecin analogue compounds, preparation method thereof and pharmaceutical compositions containing same | ɪά��ʵ���� | 2004-07-21 | — | — | CN | disclosed |
| US-6699876-B2 | FOR CANCER THERAPY | LES LABORATOIRES SERVIER (FR) | 2004-03-02 | — | — | US | disclosed |
| US-20030105109-A1 | For cancer therapy | LES LABORATOIRES SERVIER (FR) | 2003-06-05 | — | — | US | disclosed |
| US-6509345-B2 | For therapy of cancerous diseases | LES LABORATOIRES SERVIER (FR) | 2003-01-21 | — | — | US | disclosed |
| EP-1101765-B1 | Camptothecin analogues, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2002-08-14 | — | — | EP | disclosed |
| US-20020077325-A1 | New camptothecin analogue compounds | LAVIELLE GILBERT (FR) | 2002-06-20 | — | — | US | disclosed |
| CN-1301701-A | Camptothecin analogue compounds, preparation method thereof and pharmaceutical compositions containing same | ADIR (FR) | 2001-07-04 | — | — | CN | disclosed |
| EP-1101765-A2 | Camptothecin analogues, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 2001-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105109-A1 | For cancer therapy | OXER1, OXGR1, CBR1 | CCR1 18/4885CCR5 226/4885CCR8 134/4885 |
| US-20020077325-A1 | New camptothecin analogue compounds | OXER1, CBR3, CBR1 | CCR1 29/4885CCR5 98/4885CCR8 147/4885 |
| US-20240116949-A1 | SPIRO AROMATIC RING COMPOUND AND USE THEREOF | PTPN1, PTPN11, PTPN5 | CCR1 687/4885CCR5 976/4885CCR8 1040/4885 |
| US-12441743-B2 | Spiro aromatic ring compound and use thereof | PTPN1, PTPN11, PTPN5 | CCR1 687/4885CCR5 976/4885CCR8 1040/4885 |
| US-12637467-B2 | Inhibitor of BTK and mutants thereof | BTK, CNKSR1, SYK | CCR1 431/4885CCR5 579/4885CCR8 1286/4885 |
| US-20250214970-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | SCN1A, SCN3A, SCN2A | CCR1 4186/4885CCR5 4815/4885CCR8 3885/4885 |
| US-12054486-B2 | Pyridine derivatives and their use as sodium channel activators | SCN1A, SCN1B, CACNA1A | CCR1 3587/4885CCR5 4635/4885CCR8 3945/4885 |
| US-20250059189-A1 | PYRIDINE DERIVATIVES AND THEIR USE AS SODIUM CHANNEL ACTIVATORS | SCN1A, SCN1B, CACNA1A | CCR1 3759/4885CCR5 4640/4885CCR8 3938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.